I. Introduction
Coronary artery disease (CAD) and aortic stenosis (AS) hare similar risk factors and pathophysiology. 1) In managing patients with AS, we often encounter CAD. 2, 3) Several studies have reported the adverse impact of CAD in patients with AS. 4) During surgical aortic valve replacement (SAVR), concomitant coronary artery bypass grafting (CABG) is recommended in patients with significant CAD. 5, 6) However, the best strategy for CAD in patients undergoing transcatheter aortic valve implantation (TAVI) has been undetermined. There is no consensus on the indication, method and timing of revascularization. We reviewed our patients with severe AS who had undergone TAVI at our hospital, aiming to assess the prevalence of coexisting CAD, and to fi nd the optimal strategy for CAD in patients undergoing TAVI.
II. Materials and methods
Population
Between April 2010 and February 2015, we performed TAVI in 120 patients with severe AS. Severe AS was defined as meeting at least one of the following: aortic valve area less than 0.75 cm 2 , transvalvular peak pressure gradient higher than 64 mmHg and/or transvalvular mean pressure gradient higher than 40 mmHg. Among patients with symptomatic severe AS, inoperable patients or high surgical risk patients, for whom TAVI rather than SAVR was preferred, were selected by a multidisciplinary heart team. Patients with radiated chest wall, severe pulmonary dysfunction, malignant tumor, or porcelain aorta were considered to be inoperable. High surgical risks included a Logistic EuroSCORE for isolated SAVR higher than 20, a Society of Thoracic Surgeons (STS) score for isolated SAVR higher than 10 or equivalent, and other surgical risks including severe frailty and cirrhosis. In patients with complex multi-vessel CAD or left main disease with an indication for CABG, the option of SAVR with concurrent CABG was selected. 
Data collection and defi nitions
Clinical, laboratory, echocardiographic and procedural data were prospectively collected from the institutional database.
For patients with CAD, the SYNTAX score (SS) 7) and the Duke Myocardial Jeopardy Score (DMJS) 8) were calculated before and Procedural data of TAVI are listed in Table 2 . One hundred and nineteen TAVI (99%) were elective procedures, and 116 (97%) were performed under general anesthesia. Trans-femoral approach was used in 84 patients (70%). Device success rate as defined by VARC-2 criteria was 93%. Procedural data did not differ between the CAD group and non-CAD group.
Thirty-day outcomes are presented in Figure 1 . There were no differences between the CAD group and the non-CAD group for all the clinical outcomes examined, including the 30-day composite safety endpoint (18% vs 16%, p=0.86).
Patients with coronary artery disease and percutaneous coronary intervention
Among 34 patients with CAD, 15 patients (44%) underwent PCI (TAVI+PCI group) according to the above revascularization strategy. Staged PCI (PCI on an earlier date separate from TAVI) was performed in 7 patients (47% of revascularized patients)
owing to the regulation of clinical trial or matter of antiplatelet drug, and concurrent PCI (PCI with TAVI in the same session) was performed in 8 patients (53%). The clinical characteristics of TAVI+PCI group and isolated TAVI group were similar, except the rate of previous CABG (7% vs 53%, p<0.01) ( Table   3 ). Fifty percent of the lesions (12 lesions) were types A and B1
as defi ned by AHA/ACC classifi cation (Table 4) . Angiographic success rate was 100%. Procedural success rate was 96%, with one case of coronary dissection necessitating additional coronary stenting. Coronary stents were used in 24 of 25 lesions (96%; total 25 stents). Forty-six percent of all implanted coronary stents were bare metal stents and 54% were drug-eluting stents (cobalt-chromium everolimus eluting stents 21%, platinumchromium everolimus eluting stents 17%, and biolimus eluting stents 17%). Procedural data of TAVI was not different between the TAVI+PCI group and the isolated TAVI group. As for 30-day outcomes, there were also no signifi cant differences between two groups (30-day composite safety endpoint: 13% vs 21%, p=0.67).
SYNTAX score and Duke Myocardial Jeopardy Score
The SS and DMJS before and after PCI are presented in Figures 2 and 3 . In the TAVI+PCI group, SS was 7.2 2.9 before PCI, and decreased significantly to 0.5 1.1 after PCI (p< 0.01). SS in the isolated TAVI group was 6.8 6.1, and was signifi cantly higher than that in the TAVI+PCI group after PCI after PCI (p<0.01).
In the TAVI+PCI group, the DMJS before PCI was higher than that in the isolated TAVI group (5. 
IV. Discussion
Among 120 consecutive patients who underwent TAVI in our hospital, unrevascularized significant CAD was found in 34 patients (28%). Our multidisciplinary heart team decided indication of revascularization with PCI based on several factors including perfusion area and suitability for PCI. Among 34 patients with CAD, we performed PCI in 15 patients (44%) as a staged or combined procedure. PCI was uneventful and alleviated the ischemic burden of CAD.
Coronary artery disease in patients undergoing transcatheter aortic valve implantation
Previous studies have reported the presence of CAD in 34 to 64% of the patients undergoing TAVI. [10] [11] [12] [13] [14] The range of prevalence reflects the difference in definition of CAD.
Gasparetto et al. 10) defined CAD as any previous coronary revascularization or present coronary stenosis of at least 50%, while Khawaja et al. 14) defined significant CAD as coronary artery stenosis of ≥ 70% by quantitative coronary angiography. Patients with AS and coexisting CAD have been reported to be more frequently males, with higher prevalence of peripheral artery disease, previous myocardial infarction, previous PCI, previous CABG, and higher surgical risk. [11] [12] [13] The clinical characteristics of our patients are consistent with previous reports.
Indication and effectiveness of percutaneous coronary intervention
In spite of some controversial reports, CAD is generally considered a negative prognostic factor for patients with aortic stenosis. 4) However, there is no consensus on the management of CAD in patients with aortic stenosis; especially, the indication of revascularization in patients undergoing TAVI remains undetermined.
Many reports have indicated that the ischemic burden of CAD correlates with prognosis and warrants revascularization. 15, 16) In patients without aortic stenosis, we decide the indication of revascularization based on abnormal findings suggestive of significant ischemia on echocardiography, single photon emission computed tomography, or fractional fl ow reserve. For patients with aortic stenosis, however, it is difficult to use the exercise stress test or vasodilator drugs that are indispensable for the above assessments, because of possible negative effects on hemodynamics.
The SS indicates the complexity and extent of CAD. A signifi cant correlation between SS and outcome after TAVI has been reported. 12, 14) Higher SS is associated with worse prognosis following TAVI. An SS higher than 9 was identified as the optimal cut-off, with an independent association with mortality.
Using staged or concurrent PCI, we were able to decrease the A number of studies have evaluated combined TAVI and PCI therapy. 11, 13, 17, 18) In these studies, the short-term and longterm outcomes of the combined therapy were comparable to those of isolated TAVI. Our results are similar to these previous studies. PCI combined with TAVI was relatively safe and was effective to alleviate the ischemic burden of CAD. However, patients undergoing TAVI have limited life expectancy and daily activities, and the effect of combined revascularization on longterm outcome has not been determined. Interventional studies including randomized controlled trial are warranted to assess the true effectiveness of PCI combined with TAVI.
Timing of percutaneous coronary intervention
In our hospital, we generally perform PCI at the same time as TAVI, because there are some concerns about the safety of performing isolated PCI in the presence of severe AS. On the other hand, staged PCI is thought to minimize the contrast material load, radiation time, and procedural time for each session. The optimal timing of PCI is also undetermined. In this study, the amount of contrast material used and the radiation time were signifi cantly greater in the TAVI+PCI group than in the isolated TAVI group (contrast material: 187 86 vs. 111 39 ml, p<0.01, radiation time: 31 15 vs. 21 6 min, p<0.05).
Regarding the safety of PCI in the presence of severe AS, Goel et al. 19) reported that PCI can be performed in patients with severe symptomatic AS and CAD without increased risk, except in patients with low cardiac function (left ventricular ejection fractions less than 30%) and high surgical risk (STS score higher than 10) . With careful selection, staged PCI may be more acceptable to patients undergoing TAVI than concurrent PCI.
Other revascularization method
When screening for the suitability of TAVI, we selected SAVR for patients with complex multi-vessel CAD or left main disease that were indicated for CABG. Our patients who underwent TAVI had relatively simple CAD with low SS 
Limitation
The present single-center observational study included only a limited number of patients. In addition, we did not assess long-term outcomes. The findings should be interpreted with caution. It is necessary to examine the effectiveness of PCI with a prospective and long-term study.
V. Conclusion
Signifi cant CAD was found in 28% of our patients undergoing TAVI. We were able to perform PCI relatively safely in these patients, and alleviated the ischemic burden of CAD. The SS and DMJS may be useful in estimating prognosis and making decision on treatment modality for CAD in patients undergoing TAVI.
